Crucial Patent News
Fresh News, Key Updates, and Insights in the Patent Industry for Key Jurisdictions
Worldwide IP system updates by
Country
PCT
EPO
EU
USA
Patents
Patents
April 1, 2024
Patents
Industrial Designs
CHINA
INDIA
BRAZIL
Patents
On August 6, 2024, the Chinese National Intellectual Property Administration (CNIPA) implemented a reduction in intellectual property fees in line with recent legislative changes and the enforcement of legal Notices.
As per the patent costs amendments, all requests for the compensation of a patent validity term will henceforth incur a cost of 200 RMB. Should the request meet the required obligations for compensation of a patent term upon assessment, a total of 8,000 RMB will be payable as compensation for an annual patent right, with no charge being incurred for a period of 12 months or less.
Moreover, a decrease of 15% has been implemented in relation to patent
annuity fees during the patent open licensing implementation phase. Such
reductions in fees are enforceable respectively, and are not available
in conjunction with one another. Further, in case the amendment to the
name or denomonation of a patent applicant/owner is made in a bulk order
and does not involve the transfer of rights, the official fees are
charged per each change requested.
Industrial Designs
On August 6, 2024, industrial design fees in relation to applications filed via the Hague Agreement in the jurisdiction have also been altered. As such, the first and second installments of the designation fees paid may be reduced in certain cases as per the Notice of the Ministry of Finance and the National Development and Reform Commission on Issuing the ‘Measures for the Reduction of Patent Fees’” (Cai Shui [2016] No. 78), the “Notice of the Ministry of Finance and the National Development and Reform Commission on Policies for Suspending, Exempting and Adjusting Certain Administrative Fees” (Cai Shui [2018] No. 37; and the “Notice of the Ministry of Finance and the National Development and Reform Commission on Policies for Reducing Certain Administrative Fees” (Cai Shui [2019] No. 45).
Lastly, all PCT applications filed with the CNIPA as the Receiving Office which are subject to an international search are now exempt from the application fee and surcharge upon entering the Chinese PCT national phase, whilst PCT applications for which the CNIPA conducts an international search report or an international preliminary report on patentability will be exempt from the substantive examination fee when entering the Chinese national phase and requesting substantive examination.
January 20, 2024
As of January 20, 2024, several amendments to the Implementing
Regulations of the Chinese Patent Law entered into effect. These
regulations have been implemented in line with the previous revisions to
the national patent legislation enacted in 2020.
Patents
Patents
MEXICO
Canada
JAPAN
Patents
Patents
SOUTH korea
Indonesia
Trademarks
May 1, 2024
Patents
October 2024
In October 2024, the President of the Republic of Indonesia passed Law No. 65 of 2024 to amend Law No. 13 of 2016 on Patent (“Amended Patent Law”). This amendment is part of Indonesia’s ongoing efforts to strengthen its intellectual property framework and align with international standards, including the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement. The Amended Patent Law brings significant changes, expanding the scope of what can be patented. Now, in addition to products and processes, inventors can seek protection for systems, methods, and applications designed to solve specific problems. This broadened scope is crucial in today’s rapidly evolving technological landscape, where innovation often goes beyond traditional products. Additionally, the Amended Patent Law extends the disclosure period before filing a patent application (“Grace Period”) from 6 to 12 months, providing inventors with more time and flexibility.
The Amended Patent Law also introduces important changes for the pharmaceutical industry, particularly in areas like compulsory licensing and the Bolar Provision, which allows for limited use of patented inventions for research and development purposes. These amendments, along with the expanded scope of patentability, are designed to accelerate national innovation, particularly in the digital realm, while simplifying the patent administration process. This focus aligns with the goals of Industry 5.0, which aims to use technology in a way that benefits both people and the environment.
In this update, we explore the key changes introduced by the Amended Patent Law, and its implications for various sectors, including pharmaceuticals, technology, and manufacturing.
Key Changes Introduced by the Amended Patent Law
The Amended Patent Law brings important changes to Indonesia's patent system. These changes affect what can be patented and how the process works. They aim to encourage innovation and keep up with global standards. Below are the most important changes and what they mean for businesses.
Expanded scope of patentability
Previously, patent protection in Indonesia was limited to products and processes, which posed challenges for innovators in emerging fields like software and artificial intelligence. The Amended Patent Law addresses this by emphasising the patentability of problem-solving systems, methods, and applications. This will allow innovative methods such as usage techniques, software algorithms, and other digital-based solutions to be registered, ultimately diversifying patent protection in Indonesia.
Patentability of computer programs
While computer programs have always been unpatentable under Indonesian patent regulations, Article 4(d) of the Amended Patent Law introduces a valuable exception for inventions implemented by a computer. An invention implemented by a computer refers to the problem-solving ability, technical effect, and technical character driven by a computer. This amendment clarifies the requirements for computer programs to be patented. Alternatively, computer programs that do not meet these requirements can be recorded as copyright, subject to Indonesia’s copyright regulations.
Extension of Grace Period
The Amended Patent Law extends the Grace Period from 6 to 12 months. During the Grace Period, inventors will be able to exhibit their invention at official exhibitions held in Indonesia or abroad, use their invention for experimental and/or development purposes in Indonesia or abroad, and/or disclose their invention in scientific proceedings or forums. Inventions will not be considered published if a third party discloses them in violation of a confidentiality agreement within the Grace Period. The Grace Period is expanded to better accommodate the needs of inventors in submitting a patent application, such as securing adequate funding. For comparison, Japan, Australia, and the United States are among the countries implementing a 12-month Grace Period.
Simplified patent administration
Addressing previous concerns about time-consuming patent registration process, the Amended Patent Law introduces several changes to streamline patent administration. This includes an expedited publication process upon request (with a minimum of three months), allowing the invention to enter substantive examination faster. It also eases the process for patent applicants involving genetic resources and/or traditional knowledge, whereby they only need to submit statement letter stating the origin of such genetic resources and/or traditional knowledge instead of elaborating its complex process. Additionally, Article 128(2) to Article 128(6), which concerned the postponement of annual patent fee payments, has been removed in the Amended Patent Law.
Changes Impacting the Pharmaceutical Industry
The Amended Patent Law introduces significant changes that directly impact the pharmaceutical industry.
Compulsory licensing
A key change is the removal of Article 93 and the addition of Article 111A, which eliminates the compulsory licence for producing patented pharmaceutical products in Indonesia. The arrangement of compulsory licenses related to importing and exporting patented pharmaceutical products is now shifted to the scope of patent rights implementation by the government.
Bolar Provision
The Amended Patent Law revises the Bolar Provision, which allows third parties or generic drug manufacturers to experiment on a patented drug before its expiration to secure regulatory approval for marketing a generic version once the patent expires. The Bolar Provision is no longer restricted to a specific five-year period before the patent’s expiration, and its scope is broadened to cover research and regulatory approval purposes. Pharmaceutical companies may benefit from this amendment through accelerated research and development of generic drugs, as well as faster regulatory review of pharmaceutical products.
Next Steps Forward
In light of these changes, companies should proactively review their invention portfolios to identify opportunities for new patent registrations under the Amended Patent Law. This is particularly crucial for those developing digital solutions, application techniques, and innovative methods, which now have expanded protection. Stakeholders in the pharmaceutical industry should carefully analyse the revised provisions on compulsory licensing and the Bolar Provision to optimise their intellectual property strategies and adjust research and development timelines accordingly.
It is also crucial for all patent holders, particularly individual inventors and smaller patent entities, to be aware of the removal of Article 128(2) to Article 128(6). This change eliminates the possibility of postponing annual patent fee payments. Therefore, timely payment is essential to maintain patent rights.
Overall, the Amended Patent Law encourages investors to actively seek patent protection for their inventions. This is evident in several key changes, including the extension of the Grace Period for public disclosures, the option to expedite the publication process, and the broadened scope of patentable inventions. These amendments signify a positive step towards fostering innovation and strengthening Indonesia’s intellectual property landscape.
Singapore
uae
malaYsia
australia
new zealand
EAPO
saudi arabia
Patents
On August 6, 2024, the Chinese National Intellectual Property Administration (CNIPA) implemented a reduction in intellectual property fees in line with recent legislative changes and the enforcement of legal Notices.
Patents
Patents
Patents
Patents
Patents
Translate & File Patents With PatentRegistrar.com

Our team consists of experienced patent attorneys based in the 20+ most popular countries for patenting and partners in other coutries, ensuring seamless support at every stage of your transition to the national phase. We have trusted experts in key jurisdictions such as the United States, EU, China, Japan, India, Canada, Brasil, etc. With their local expertise and our centralized management, we make the process efficient, reliable, and stress-free.
Explore Patent Translation & Filing Country Packages
Browse Patent Translation & Filing Prices by Country
Features
ALL-IN-ONE SOLUTION
Forget the hassle of navigating different countries' requirements and trying to meet every standard on your own. With our ALL-IN-ONE solution, everything is simplified into a single, seamless process. ALL-IN-ONE SERVICE includes Translation, Application formating and Filing, Government and Professional fee.
ACCURATE TRANSLATIONS, CERTIFYED TRANSLATIONS
Affordable and accurate translations of your patent documents, tailored to meet the specific requirements of each jurisdiction. Our team of 50 licensed patent translators ensures precise and reliable translations for just $899, with optional certification available for an additional cost.
BEST EXPERTS IN 20+ COUNTRIES
Our team comprises 20+ highly skilled registered national patent attorneys, each with extensive backgrounds in their respective countries. Their deep expertise ensures precise, efficient, and compliant support for your national phase entry needs.
AMAIZING PRICES for HIGH QUALITY SERVICES
We offer uniquely low prices that you won’t find anywhere else on the market. Our cost-effective solutions ensure top-quality service.